


PO127 — 2021

AAO

Quality of Life With Bilateral Implantation of a New EDOF-IOL



Cataract

Presented on Saturday, November 13, 2021 6:00 AM

Author(s): Cathleen M McCabe MD; John P Berdahl MD; Mukesh Dhariwal; Amit Gupta, MS; Hemant Rathi, MS;

Purpose This study compared the lifetime vision-related quality of life gain with bilateral AcrySof IQ Vivity EDF IOL versus bilateral aspheric AcrySof IQ SN60WF IOL. **Methods** Incidence of postoperative spectacle dependence, rate of bothersome visual disturbances and lens explantation rates were derived from a randomized clinical study (NCT03274986). Type of spectacle need (readers/distance/bifocal/progressive) for each intervention and duration and resolution rate of bothersome visual disturbances were provided by expert inputs. Utility associated with health states: severe glare/haloes/starbursts, spectacle dependence and IOL explantation were sourced from literature. Quality adjusted life years (QALYs) for each intervention was estimated using Markov model. **Results** Over lifetime horizon, accrued QALYs were 12.05 and 11.84 for patients receiving AcrySof IQ Vivity EDF IOL and SN60WF, respectively, leading to an incremental QALY gain of 0.21 for patients receiving EDF IOL. **Conclusion** Bilateral AcrySof IQ Vivity EDF IOL provides greater vision-related quality of life gain for presbyopic cataract patients versus SN60WF

Disclosure: Cathleen M McCabe MD: Abbvie: C; Alcon Laboratories, Inc.: C,L,S; Allergan: C,S; Bausch Lomb: C,L; Dompe: C; EyePoint Pharmaceuticals: C,L,S; Glaukos Corporation: L,S; Ivantis: C,L,O,S; Johnson & Johnson Vision: S; Novartis Pharma AG: C,L; Ocular Innovations: C,O; Ocular Therapeutix: C,L,S; Omeros: C,L; Ora, Inc.: S; Science Based Health: C; Sight Sciences, Inc.: C; Sun Ophthalmics: C,L; Tarsus: C; Zeiss: C,L;